Antiviral therapy without interferon improved liver function in patients with hepatitis C virus infection-related advanced cirrhosis, according to data from an observational cohort study.
Researchers analyzed data of 80 patients with HCV-associated liver cirrhosis undergoing treatment with a combination of direct-acting antivirals without interferon. Of these patients, 43% had Child-Pugh B/C cirrhosis (n = 34), and 53% had platelet counts of less than 90,000/μL (n = 42). The combination regimens included Sovaldi (sofosbuvir, Gilead Sciences) with ribavirin (n = 56), Olysio (sofosbuvir/simeprevir, Janssen Therapeutics) with or without ribavirin (n = 15) and sofosbuvir and Daklinza (daclatasvir, Bristol-Myers Squibb) with or without ribavirin (n = 9). Most patients had HCV genotype 1 (n = 50), followed by 24 with genotype 3, four with HCV genotype 2 and two patients with genotype 4.
Continue reading..
Full text
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies
Full text
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies
No comments:
Post a Comment